Spots Global Cancer Trial Database for acute myeloblastic leukemia
Every month we try and update this database with for acute myeloblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | NCT00487448 | Myelodysplastic... Acute Myeloblas... | Fludarabine Cytarabine G-CSF Idarubicin Peripheral bloo... Bone marrow tra... | - 75 Years | PETHEMA Foundation | |
| Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | NCT00890929 | Acute Myeloid L... Adult Acute Mye... | Lenalidomide Azacitidine | 60 Years - | Stanford University | |
| LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | NCT01041040 | Acute Myeloblas... | gemtuzumab | - | PETHEMA Foundation | |
| Treatment of Acute Myeloblastic Leukemia in Younger Patients | NCT00390715 | Acute Myeloblas... | chemotherapy | - 65 Years | PETHEMA Foundation | |
| Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children | NCT00552825 | Acute Lymphobla... Acute Myeloblas... Solid Tumors, Hodgkin's Disea... Non-Malignant | 3 Years - 7 Years | Sheba Medical Center | ||
| Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients | NCT00504920 | Myelodysplastic... Acute Myeloblas... Leukemia | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant | NCT00354120 | Acute Myeloblas... Lymphoblastic L... Myelodysplasia Chronic Myeloid... Myelofibrosis Lympho-prolifer... | Alentuzumab Globulina antil... | 18 Years - 65 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 | NCT04452604 | Acute Myeloblas... Acute Lymphobla... SARS-CoV-2 | 18 Years - | French Innovative Leukemia Organisation | ||
| Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia | NCT01966497 | Acute Myeloblas... Aged Higher Tha... | 60 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 | NCT04452604 | Acute Myeloblas... Acute Lymphobla... SARS-CoV-2 | 18 Years - | French Innovative Leukemia Organisation | ||
| Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT | NCT05696457 | Acute Myeloblas... Hematopoietic S... | Passive music t... | 18 Years - | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | |
| LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | NCT01041040 | Acute Myeloblas... | gemtuzumab | - | PETHEMA Foundation | |
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | NCT00487448 | Myelodysplastic... Acute Myeloblas... | Fludarabine Cytarabine G-CSF Idarubicin Peripheral bloo... Bone marrow tra... | - 75 Years | PETHEMA Foundation | |
| Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia | NCT05499611 | Acute Myeloblas... | 18 Years - 65 Years | University Hospital, Bordeaux | ||
| PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years | NCT01296178 | Acute Myeloblas... | IDARUBICINE ARA-C | - 65 Years | PETHEMA Foundation | |
| Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia | NCT05499611 | Acute Myeloblas... | 18 Years - 65 Years | University Hospital, Bordeaux | ||
| RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML | NCT01307241 | Acute Lymphobla... Acute Myeloblas... | 15 Years - | National Institute of Cancerología | ||
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 | NCT04452604 | Acute Myeloblas... Acute Lymphobla... SARS-CoV-2 | 18 Years - | French Innovative Leukemia Organisation | ||
| Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT | NCT05696457 | Acute Myeloblas... Hematopoietic S... | Passive music t... | 18 Years - | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | |
| Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft | NCT03280290 | Acute Myeloblas... | blood | 18 Years - | University Hospital, Lille | |
| Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft | NCT03280290 | Acute Myeloblas... | blood | 18 Years - | University Hospital, Lille | |
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 | NCT04452604 | Acute Myeloblas... Acute Lymphobla... SARS-CoV-2 | 18 Years - | French Innovative Leukemia Organisation | ||
| Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | NCT00890929 | Acute Myeloid L... Adult Acute Mye... | Lenalidomide Azacitidine | 60 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
